University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Neil Dunavin, MD, MS

Assistant Clinical Professor, Division of Hematology and BMT, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

Clinical hematologist with interests including: stem cell transplantation, cellular therapy, leukemia, myelodysplastic syndrome, bone marrow failure, and clinical trials.

Education

  • University of Kansas Medical School, Kansas City, Kansas, MD, 05/2009, Medicine
  • Internal Medicine Residency, Ohio State University Hospitals, Columbus, Ohio, 06/2012, Internal Medicine
  • Internal Medicine Chief Residency, Ohio State University Hospitals, Columbus, Ohio, 06/2013, Internal Medicine
  • Hematology Fellowship, National Institutes of Health Clinical Research Center, Bethesda, Maryland, 06/2015, Hematology
  • Post-Graduate Fellowship, National Institutes of Health Clinical Research Center, Bethesda, Maryland, 06/2016, Stem Cell Transplantation
  • NIH-Duke Clinical Research Training Program, Duke University, Durham, North Carolina, MHS, 05/2016, Clinical Research

Professional Experience

  • 10/2019 - present
    Assistant Clinical Professor, Division of Hematology and BMT, UCSF
  • 07/2016 - 09/2019
    Assistant Professor, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas

Honors & Awards

  • 05/2004
    Phi Beta Kappa, University of Kansas
  • 05/2011
    Outstanding Resident Educator Awarded by Medical Students, OSUMC
  • 05/2011
    Clara D. Bloomfield Excellence in Hematology/Oncology Research Award, OSUMC
  • 12/2011
    Travel Award, American Society of Hematology Annual Meeting
  • 05/2012
    Chairman's Award for Scholarly Achievement by a Senior Internal Medicine Resident, OSUMC
  • 05/2012
    Sara Medwid Gorsline Memorial Award for Excellence in Internal Medicine, OSUMC
  • 05/2012
    Resident Peer Teaching Award, OSUMC
  • 09/2015
    ISCT-ASBMT Cell Therapy Training Course Scholar

Selected Publications

  1. Dunavin N, Mau LW, Meyer CL, Divine C, Abdallah AO, Leppke S, D'Souza A, Denzen E, Saber W, Burns LJ, Ganguly S. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. Biol Blood Marrow Transplant. 2020 Jan 07.
    View on PubMed
  2. Vekaria PH, Kumar A, Subramaniam D, Dunavin N, Vallurupalli A, Schoenen F, Ganguly S, Anant S, McGuirk JP, Jensen RA, Rao R. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Leukemia. 2019 07; 33(7):1675-1686.
    View on PubMed
  3. Gao B, Lin J, Jiang Z, Yang Z, Yu H, Ding L, Yu M, Cui Q, Dunavin N, Zhang M, Li M. Upregulation of chemokine CXCL10 enhances chronic pulmonary inflammation in tree shrew collagen-induced arthritis. Sci Rep. 2018 07 03; 8(1):9993.
    View on PubMed
  4. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A. Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematol. 2018; 139(1):52-57.
    View on PubMed
  5. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A. Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematol Oncol Stem Cell Ther. 2018 Sep; 11(3):135-141.
    View on PubMed
  6. Dunavin N, Dias A, Li M, McGuirk J. Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease? Biomedicines. 2017 Jul 01; 5(3).
    View on PubMed
  7. Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leuk Res Rep. 2017; 7:40-44.
    View on PubMed
  8. Anandi P, Tian X, Chinian F, Cantilena CR, Dunavin N, Hensel N, Draper D, Koklanaris E, Maxwell S, Superata J, Muranski P, Battiwalla M, Paczesny S, Barrett AJ, Ito S. Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system. Bone Marrow Transplant. 2016 12; 51(12):1615-1616.
    View on PubMed
  9. Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, Townsley DM, Dumitriu B, Battiwalla M, Rezvani K, Young NS, Barrett AJ, Ito S. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016 Nov; 175(3):427-439.
    View on PubMed
  10. Anand A, Anandi P, Jain NA, Lu K, Dunavin N, Hourigan CS, Le RQ, Chokshi PD, Ito S, Stroncek DF, Sabatino M, Barrett AJ, Battiwalla M. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Support Care Cancer. 2016 Feb; 24(2):815-822.
    View on PubMed
  11. Le RQ, Tian X, Jain NA, Lu K, Ito S, Draper DA, Anandi P, Hourigan CS, Dunavin N, John Barrett A, Battiwalla M. Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1138-40.
    View on PubMed
  12. Chokshi P, Anandi P, Jain N, Dunavin N, Le RQ, Ito S, Barrett J, Battiwalla M. Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell-Depleted Human Leukocyte Antigen-Matched Sibling Transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):954-5.
    View on PubMed
  13. Bond DA, Dunavin N, Otterson GA. Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease. Cancer Invest. 2015 Mar; 33(3):86-8.
    View on PubMed
  14. Andritsos LA, Dunavin N, Lozanski G, Jones JA, Blachly JS, Lucas DM, Byrd JC, Kraut E, Grever MR. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica. 2015 Jan; 100(1):e18-20.
    View on PubMed
  15. Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma. 2013 Aug; 54(8):1658-64.
    View on PubMed

Go to UCSF Profiles, powered by CTSI